Moreover, metformin may abrogate HER-2-induced tumor angiogenesis via targeting the HER2/HIF-1α/VEGF pathway and is associated in a dose-dependent manner with inhibition of HER2-positive gastric cancer cell growth, also via reduction of HER 2 phosphorylation [111,115]. Here, ERBB2 is linked to neoplasm.